Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.
Trigeminal neuralgia (TN) is a severe chronic pain disorder with limited treatment options. Our recent webinar brought together experts to explore its mechanisms and discuss innovative therapeutic strategies.
We were honoured to hear from Professor Michael Gold, PhD, from the University of Pittsburgh, who shared key findings on TN's unique pathology and the challenges of modelling the disorder. He highlighted the difficulties in replicating TN in animal studies, differences in gene expression between trigeminal and somatic nerves, and the role of specific genes in action potential propagation. His insights emphasized the complexity of TN and the need for better preclinical models to advance treatment development.
Anthony M. Rush, PhD, Director of Neuroscience at Metrion, presented on the role of pain drug discovery assays in advancing novel treatments. He emphasised the importance of translational assays in pain therapeutics and how sensory neuron-based assays can enhance the success rate of drug candidates. His talk underscored the critical role that robust preclinical assays play in identifying and validating new pain treatments.
We extend our sincere gratitude to Professor Michael Gold and Dr. Anthony M. Rush for sharing their expertise and to all attendees for their engagement and insightful questions. Your participation contributes to ongoing advancements in the field of chronic pain research.
Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.
Alex Haworth, Senior Scientist at Metrion, introduces a poster demonstrating Metrion's development of a monoclonal CHO cell line expressing hNav1.9, validated via manual and automated patch clamp techniques.